Overview

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Calcitonin
Calcitonin Gene-Related Peptide
Katacalcin
Salmon calcitonin
Teriparatide